Viking Therapeutics commercial chief exits after nine months; Gilead eyes BeOne executive for China growth
read at Endpoints ↗Neutral
Viking Therapeutics' chief commercial officer Neil Aubuchon left the company after only nine months in the role, according to Peer Review.
His brief tenure has sparked speculation about the company's strategy for its obesity drug pipeline, though no further details were provided.
Meanwhile, Gilead Sciences is reportedly evaluating a senior executive from BeOne to lead its expansion efforts in China, signaling continued focus on growth in the Asian market.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Viking commercial chief is out in a hurry; Gilead looks to BeOne exec for China expansion”
read at Endpoints ↗95 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that